Drug intelligence / Profile preview

ipilimumab + dabrafenib

Development stage: Preclinical
Lead developer: Bristol Myers Squibb
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

A combination therapy consisting of ipilimumab, an anti-CTLA-4 monoclonal antibody immunotherapy, and dabrafenib, a BRAF kinase inhibitor. This combination pairs an immune checkpoint inhibitor with a targeted therapy for the treatment of advanced melanoma with BRAF V600 mutations. Ipilimumab works by blocking the CTLA-4 checkpoint, promoting T-cell function and growth to enhance immune response against cancer cells. Dabrafenib inhibits mutated BRAF kinase, disrupting the MAPK pathway and decreasing cell proliferation in cancer cells with BRAF V600 mutations.

Targets

CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)BRAF V600E

Beyond the preview

Go deeper on ipilimumab + dabrafenib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ipilimumab + dabrafenib.

Explore the full profile